(2025). Multicenter upfront randomized phase II trial of quizartinib and high-dose cytarabine plus mitoxantrone in relapsed/refractory acute myeloid leukemia with FMSlike tyrosine kinase 3 internal tandem duplication. Haematologica - the Hematology journal.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Multicenter Upfront Randomized Phase II Trial of Quizartinib and High-dose Cytarabine Plus Mitoxantrone in Relapsed/refractory Acute Myeloid Leukemia with FMSlike Tyrosine Kinase 3 Internal Tandem Duplication."
Haematologica - the Hematology Journal 2025.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Multicenter Upfront Randomized Phase II Trial of Quizartinib and High-dose Cytarabine Plus Mitoxantrone in Relapsed/refractory Acute Myeloid Leukemia with FMSlike Tyrosine Kinase 3 Internal Tandem Duplication."
Haematologica - the Hematology Journal, 2025.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.